promoter less gene targeting without nucleases ameliorates haemophilia b mice 
site-specific gene addition can allow stable transgene expression gene therapy possible preferred use promiscuously integrating vectors sometimes associated clonal expansion1 oncogenesis2 site-specific endonudeases can induce high rates targeted genome editing finding increasing applications biological discovery gene therapy3 however two safety concerns persist: endonudease-associated adverse effects on-target4 off-target56; oncogene activation caused promoter integration even without nucleases7 perform recombinant adeno-associated virus raav-mediated promoterless gene targeting without nucleases demonstrate amelioration bleeding diathesis haemophilia b mice particular target promoterless human coagulation factor ix f9 gene liver-expressed mouse albumin alb locus f9 targeted along preceding 2a-peptide coding sequence integrated just upstream alb stop codon f9 fused alb dna rna levels two separate proteins synthesized way ribosomal skipping thus f9 expression linked robust hepatic albumin expression without disrupting injected aav8-f9 vector neonatal adult mice achieved on-target integration similar % albumin alleles hepatocytes established f9 produced on-target integration ribosomal skipping highly efficient stable f9 plasma levels -% normal obtained treated f9-deficient mice normal coagulation times conclusion transgene integration 2a-fusion highly expressed endogenous gene may obviate requirement nucleases and/or vector-borne promoters method may allow safe efficacious gene targeting infants adults greatly diminishing off-target effects still providing therapeutic levels expression integration 
